Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnormal blood cells, or reduced peripheral blood cell count. Recent clinical studies on combination therapy of decitabine (DAC) and arsenic trioxide (ATO) have demonstrated synergy on MDS treatment, but the treatment can cause significant side effects to patients. In addition, both drugs have to be administered on a daily basis due to their short half-lives. In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by copackaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTNPs). Our pharmacokinetic studies revealed that intravenously administered BTNPs increased circulation time up to 3 days. Biodistribution analysis showed that the BTNP facilitated DAC and ATO accumulation in the bone, which is 6.7 and 7.9 times more than untargeted NP. Finally, MDS mouse model treated with BTNPs showed better restoration of complete blood count to normal level, and significantly longer median survival as compared to free drugs or untargeted NPs treatment. Our results support bone-targeted co-delivery of DAC and ATO for effective treatment of MDS.
Introduction
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders or clonal hematopoietic stem cell disorders characterized by abnormal blood cells (dysplasia), or reduced peripheral blood cell count (cytopenia), and has the risk of transformation to acute myeloid leukemia, primarily in the elderly population. Morbidity and mortality in MDS are mostly caused by cytopenia and transformation to leukemia [1] . Currently, the goal of MDS treatment is to achieve hematologic improvement and alteration of the natural progression of the disease [2] . Despite variety of treatments developed in the past years, the use of a single therapeutic agent remains limited by the biological heterogeneity of MDS and its complex mechanism [3, 4] . Instead, combination therapies using multiple therapeutic agents have been proposed to eradicate MDS cells by exploiting synergistic effects among drugs, and to reduce adverse effects. It was shown in a recent trial that the combination of decitabine (DAC) and arsenic trioxide (ATO) almost tripled the response rate in MDS patients compared to single agent therapies [5] [6] [7] . The synergistic effect was reflected by the dual-action of inhibition of methylation and induction of leukemia stem cell apoptosis [8] . However, systemic toxicity from DAC and ATO is a major cause for concern. For example, daily and continued administration of ATO for single agent treatment of MDS has been reported to cause lethal hepatic damage in clinic [9, 10] . Some studies have shown that nonspecific global demethylation generated by DAC may lead to global chromosomal instability and contribute to neoplasm [11, 12] . Moreover, because of the short half-lives of both DAC and ATO, daily administration is necessary to sustain therapeutic effect. The continuous injections of these two drugs have several drawbacks such as increased cost and poor patient compliance. These problems highlight the urgent need in targeting these two drugs in disease tissue to reduce systemic toxicity and to sustainably release these drugs over time so as to improve patient compliance.
Nanomedicine has been addressing toxicity and delivery issues of systemically administered drug for several decades now [13] . In this field, various nanoformulations have been explored to co-deliver therapeutic agents to treat different diseases. Examples include nanoscale polymer particles for co-delivery of oxalipltin and gemcitabine [14] , carboxymethyl chitosan micelle for doxorubicin and cisplatin [15] , liposomes for oxaliplatin and cetuximab [16] , mesoporous silica nanoparticles for cisplatin and phthalocyanine [17] , pH sensitive hydrogel for paclitaxel and doxorubicin [18] . Up to now, there has been no nanomedicine reported to successfully co-deliver drugs for treatment of MDS. However, there are two types of nanoparticles loaded with single drugs reported to treat MDS: magnetic nanoparticle (MNPs-Fe 3 O 4 ), and PLA-PEG polymeric nanoparticle. The efficacy of MNPs-Fe 3 O 4 was only evaluated on MDS cells [19] . On the other hand, PLA-PEG nanoparticle loaded with AZD2811, termed Accurins, is currently in clinical trial stage. Although Accurins has improved toxicity and antitumor activity through slow release kinetics of PLA-PEG polymer nanoparticles, its non-specific distribution and release still result in significant systemic toxicity [20] . Thus, to maximally enhance therapy efficacy and reduce systemic toxicity of chemotherapy drugs, effective targeted delivery of drug molecules to the bone marrow where MDS cells reside is still an urgent need. Alendronate (ALN), a bisphosphonate, has emerged in recent years as a highly effective bone or bone microenvironment targeting ligand thanks to its strong chelation with the calcium ion of mineral hydroxyapatite (HA), the main ingredient of bone marrow niches [21] . Different bone targeted delivery systems based on bisphosphonates, especially alendronate, have been developed for the treatment of bone-related cancers. These systems mainly include polymeric (PTX-PEG-ALN, DOX-hyd-PEG-ALN) [22, 23] and liposomal (LIP-ALN) nanoparticels [24] . However, these two kinds of bone-targeted nanoparticles have their intrinsic drawbacks. In fact, liposomes lack stability, high drug loading, and sustained-release properties, whereas polymeric nanoparticles aggregate easily due to their hydrophobic surface [25] . In this work we developed alendronate-conjugated bonetargeting nanoparticles (BTNPs) to co-deliver DAC and ATO to bone marrow for treatment of MDS. The core of BTNPs consists of a poly (D, Llactide-co-glycolide)-cholesterol polymer that releases the drugs in a controlled fashion, and the shell is made of alendronate-PEG-lipid designed to target bone marrow. BTNPs combine the advantages of both polymeric nanoparticles and liposomes to obtain efficient drug encapsulation, time-tunable drug release profile, and bone marrow targeting potential [25] [26] [27] . In addition, all components of BTNPs are biodegradable, biocompatible, and FDA-approved, thus making BTNPs suitable for clinical translation. Overall, the purpose of BTNPs is to codeliver of DAC and ATO and increase enrichment of the drugs in bone marrow microenvironment, which may enhance synergistic treatment of MDS and reduce systemic toxicity of chemotherapeutics.
Materials and methods

Materials
DAC and ATO were purchased from LC laboratories (Boston, MS, USA). RPMI 1640 and fetal bovine serum (FBS) were obtained from Thermo Fisher (Waltham, MA, USA). FITC-AnnexinV and 7-AAD were ordered from Invitrogen (Carlsbad, CA, USA). poly (D, L-lactide-co-glycolide)-cholesterol (5050) (inherent viscosity: 0.59 dL/g, average Mn: 38 kDa) was purchased from PolySciTech (West Lafayette, USA). Alendronate sodium trihydrate, polyvinyl alcohol and primer were ordered from Sigma-Aldrich (St. Louis, MO, USA). 1, 2-Distearoyl-snglycero-3-phosphoethanolamine-N-[carboxy (polyethylene glycol)-2000] was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA).
Bone marrow cell isolation and culture
Bone marrow cells were extracted from the femur and tibia of wildtype and MDS-bearing mice by flushing the bone marrow cavity with 2% FBS in PBS using 25G needles. Collected cells were centrifuged at 1500 rpm for 3.5 min and then resuspended in the ammonium-chloridepotassium lysis buffer for 20 s to lyse red blood cells. Cells were then centrifuged at 1500 rpm for 3.5 min, resuspended in 2% FBS, and then filtrated using a sterile cell strainer with 70 μm nylon mesh. The collected bone marrow cells were cultured in RPMI 1640 medium enriched with m-IL-6, m-IL-3 and m-SCF in a 37°C incubator. Smears of a portion of the collected fresh bone marrow cells were also stained by the Wright-Giemsa method.
Preparation of alendronate-PEG-DSPE
25 mg of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(Poly ethylene glycol)-2000] (DSPE-PEG-COOH) were dissolved in acetone and methanol (about 10 mg/mL), and then the solution was added drop by drop into ten times volume of phosphate buffer (50 mM, pH 7.2), and left stirring for 4 h at room temperature. The lipid micelle solution was concentrated to 1 mL and transferred to 1.5 mL tube. Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) (both 2 equivalent of Carboxylic acid groups) were added to the lipid micelle solution, and stirred for 1 h at room temperature. The lipid micelle solution was diluted adding 4 mL Mill-Q water, and then excess EDC and NHS from the diluted solution were removed using 3KDa ultra-centrifuge filters. 20 mg of Alendronate were dissolved in 1 mL sodium borate buffer (pH 8.5, 100 mM), then added to the concentrated lipid micelle solution and stirred overnight at room temperature. Alendronate conjugated lipid was transferred to 2000 MWCO benzoylated cellulose dialysis bag and dialyzed against water for 24 h at room temperature. The water was changed for 4 times. The dialyzed conjugated lipid was lyophilized, yielding to about 21.0 mg of white powder. The dried conjugated lipid powder was dissolved in acetone, then flushed with nitrogen to dry, and stored at 4°C until use.
Preparation of DAC and ATO encapsulated BTNPs
100 μL of ATO and DAC dissolved in NaOH (3 mg/mL) was added into a solution of 50 mg poly (D, L-lactide-co-glycolide)-cholesterol dissolved in 1 mL dichloromethane under vortex to form a W/O primary emulsion. The primary emulsion was added into 1.6 mL of 5% polyvinyl alcohol and 2 mg/mL of alendronate-poly (ethylene glycol)-1, 2-distearoylsn-glycero-3-phosphoethanolamine (Alendronate-PEG-DSPE). The resulting emulsion was then sonicated three times for 30 s at 70 Hz. The mixture was then added to 100 mL of 0.2% polyvinyl alcohol, and left stirring for 3 h to remove the organic solvent. Particles were washed by centrifugation at 10,000 rpm for 20 min at 4°C, and then washed three times with deionized water. The collected particles were lyophilized and stored at − 20°C [28] . BTNPs loaded with only DAC or ATO were prepared as control following the same process. Untargeted nanoparticles (Untargeted NPs) were prepared by the same process using DSPE-PEG-COOH. To measure particle size, empty BTNPs were dispersed homogeneously in deionized water at 2 mg/mL by ultrasonication. Size and zeta potential of BTNPs were measured using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK) following the manufacturer recommended protocols. All measurements were confirmed by triplicates, and results refer to the mean of three measurements/one of the triplicates is shown. Topographical images of BTNPs using atomic force microscopy atomic force microscopy (AFM) imaging in air was performed on a dry sample of NP deposited on a silicon slide to confirm particles' morphology. Particles were imaged using a commercial silicon cantilever in tapping mode at a scanning rate of 0.5 Hz from a 0°X angle. Images were processed by fitting each scan line to polynomial leveling functions [29] .
Structure analysis of BTNPs
A negative stain was used to examine the lipid layer on surface of BTNPs with transmission electron microscopy (TEM), following a previously reported procedure [30] . Briefly, BTNPs were diluted in deionized water at 2 mg/mL and sonicated. Samples were then prepared by placing one drop of 10 times diluted BTNPs on a carbon-coated copper grid. After air dry for 10 min on the grid, particles were stained with 2% phosphotungstic acid for 15 min. The stained samples were imaged using a TEM (3H-7000FA; Hitachi Ltd.). Scanning electron microscopy (SEM) was used to observe the solid core of polymer structure. The BTNPs dispersed in deionized water at 2 mg/ml were dropped onto a silica slide and allowed to dry. To enhance conductivity, a 5 nm think gold layer was deposited onto the sample before imaging.
Measurement of drug loading and encapsulation efficiency in BTNPs
Five formulations of BTNPs including different ratio of DAC/ATO (w/w) was performed listed in Table S1 : BTNPs (0:1), BTNPs (0.5:1), BTNPs (1:1), BTNPs (2:1) and BTNPs (3:1). The amount of DAC in BTNPs was measured using high performance liquid chromatography (HPLC) following a procedure previously published [31] . Briefly, dried BTNPs were dissolved into dimethyl sulfoxide under vortex for 60 s, and centrifuged at 10,000 rpm for 10 min. The supernatant was collected and applied for HPLC separation. The mobile phase was 0.14 M acetic acid and acetonitrile, and gradient elution (starting at 10% acetonitrile and ending at 90% acetonitrile after 20 min) was used to separate DAC. DAC was detected at a wavelength of 230 nm. The retention time of DAC was 9.7 min. The standard curve was obtained in the range between 5 and 500 ng/mL with regression eq. Y = 125.23X − 147.568 and correlation coefficient R 2 = 0.9994. The amount of ATO in BTNPs was determined using an inductively coupled plasma (ICP) method, as previously described [32, 33] . To prepare samples, dried nanoparticles were dissolved in methanol and acetonitrile (3:1), and centrifuged at 12,000 rpm for 10 min. The supernatant was carefully removed, and the precipitate was dissolved in 0.1 M NaOH and used for ICP analysis. The drug loading (DL) and encapsulation efficiency (EE) were calculated as DL = (W 1 /W) × 100%, and EE = (W 1 /W 2 ) × 100%, where W 1 is the mass of drug loaded in nanoparticles, W 2 is the initial amount of drug added in solution for the loading, and W is the mass of nanoparticles.
In vitro drug release from BTNPs
In vitro drug release profiles were performed in PBS, pH 7.4. Briefly, 10 mg of BTNPs were dispersed into 2 mL PBS and incubated in air at 37°C with shaking at 500 rpm. After centrifugation at 12,000 rpm, 4°C for 10 min, the supernatant was collected and analyzed following the method for drug loading at interval time. 2 mL of fresh PBS solution was added to the tube for the next readings. A time-dependent accumulative release curve was generated by repeating this at different times. , and 100 μg/mL) in triplicates. Based on the ratio of DAC/ATO in each formulation, the corresponding DAC concentrations can be calculated for each formulation. Cells were cultured for 72 h before evaluated for cell viability. To measure cell viability, 10 μL of MTT reagent was added to each well and incubated at 37°C for 4 h before dimethyl sulfoxide was added into each well. Optical density (OD) values were measured at 590 nm using a microplate reader. Percentage of cell survival was calculated using untreated cells as the control. Synergistic inhibition effect was defined as CI < 1.
Cytotoxicity of BTNPs
Apoptosis analysis of bone marrow cells
Apoptosis was analyzed with annexin V-fluorescein isothiocyanate (FITC)/7-AAD double staining following a previously published procedure [34] . Briefly, MDS mouse bone marrow cells (1 × 10 5 cells/mL) were seeded in 6 well plates and treated with free DAC + ATO, DAC/ ATO untargeted NPs, and DAC/ATO BTNPs with an equivalent concentration of ATO of 0.1 μg/mL for 24 h. Then, cells were stained with Annexin V-FITC/7-AAD dye according to the manufacturer's instructions. Cells treated with PBS were used as control. Finally, cells were harvested and used for flow cytometry, H & E staining or fluorescence microscopy.
In-vitro colloidal stability of BTNPs
BTNPs were dispersed in 50% fetal bovine serum (FBS, GenDEPOT, TX, USA) solution at 2 mg/mL. At each time point, an aliquot of BTNPs solution was collected to measure BTNPs size using the same method described in Section 2.5.1.
Pharmacokinetics studies
Untargeted nanoparticles and BTNPs were injected into MDS mice via intravenous injection at doses of 6.6 mg/kg DAC and 3.3 mg/kg of ATO. Blood samples were collected into EDTA-K tube by retro-orbital bleeding at scheduled time points. Plasma was separated by centrifuging at 4°C at 3000 g for 15 min. Each plasma sample was divided into two parts, one for DAC measurement and the other for ATO measurement, respectively. Briefly, 200 μL plasma was mixed with a solution of chloroform and methanol (1:3, v/v) under vortex for 120 s. The mixture was then centrifuged at 12,000 g for 10 min. The organic layer was collected and dried under vacuum following a previously published procedure [35] , and then dissolved in 50 μL 0.1 M NaOH. Concentration of DAC in this aliquot was measured by HPLC as described in Section 2.5. ATO concentration in the other aliquot was directly diluted with deionized water and used to analyze ATO by ICP as described in Section 2.5.
Bone targeting ability of BTNPs
The bone targeting ability of BTNPs was investigated in MDS mice. Alexa 647-labeled lipids were encapsulated into BTNPs to track distribution of nanoparticle in vivo. 24 h prior to imaging, 1 mg of Alexa 647-labeled lipid-polymer nanoparticles dispersed in phosphate buffer saline (PBS) was injected intravenously. Whole body fluorescence images were taken with an in vivo imaging system (IVIS). Mice injected with fluorescent dye Alexa 647, untargeted particles were used as a control for bone targeting ability. Mice injected with PBS were used to evaluate background fluorescence. Each mouse had > 30 point source selections. Quantitative imaging analysis of fluorescence was performed using Living Image Software 4.2 (Caliper Life Sciences, Hopkinton USA).
Tissue biodistribution analysis
For tissue distribution study, MDS mice were sacrificed at 24 h after treatment with 6.6 mg/kg DAC and 3.3 mg/kg ATO. Tissues were collected and homogenized in PBS followed by the addition of a fourfold volume of extraction solution of chloroform and methanol (1/3, v/v). The mixture was vortexed for 30 min and then centrifuged at 12,000 rpm for 15 min. Each organ processed as described was then separated into two parts [36, 37] . One part was processed for HPLC analysis of DAC content following the procedure described in Section 2.5. The dried organic layer was dissolved in 200 μL 0.1 M NaOH and analyzed using HPLC as described above. The other aliquot was used for ICP analysis of ATO as described above. Femur bone samples were incubated in 14 M HNO 3 at 110°C until dried. And then one parts of the powder was dissolved into 0.1 M NaOH for analysis of DAC. The other parts were dissolved into 0.05 M HNO 3 for analysis of ATO. DAC and ATO were then analyzed using HPLC and ICP as described in Section 2.5, respectively.
Therapeutic efficacy studies
All animal studies described above were in accordance with guidelines determined by the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals, and complied with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the Houston Methodist Research Institute. NUP98/HOXD13 transgenic mice [C57BL/6-Tg (Vav1-NUP98/HOXD13) G2Apla/J, Jackson Laboratory] were used as animal model to develop MDS upon aging. To evaluate the efficacy of BTNPs in vivo, MDS mice (n = 16 mice) were treated with 1) PBS, 2) a solution of free DAC and ATO, 3) untargeted DAC/ATO-NPs, or 4) BTNPs for 4 weeks. PBS and free drug groups were administered daily. NPs and BTNPs groups were administered twice per week. Each group was treated with doses of 6.6 mg/kg DAC and 3.3 mg/kg ATO at each time point. Complete blood count (CBC) was monitored weekly during treatment. Smears of peripheral blood were also stained by the Wright-Giemsa method.
Real-time RT-PCR analysis
Total RNA was isolated from MDS bone marrow cells using RNeasy Mini kits was used to synthesize cDNA. cDNA and DNMT1 primer were mixed with Premix Ex Taq for real-time PCR analysis. Real-time PCRs data were processed on an Mx3000 multiplex quantitative PCR system. The DNMT1 primers used for real-time PCR analysis were 5′-CCTAGTTCCGTGGCTACGAGGAGAA and 5′-TCTCTCTCC T CTGCAGC CGACTCA.
Statistical analysis
All data's error bars are reflected as the mean ± SEM. The 2-tailed Student's t-test was applied to compute P values between two groups. Log-rank analyses were used to analyze significance in Kaplan-Meier survival curves. GraphPad Prism software was used to carry out all statistical analyses. *p < 0.05, **p < 0.01, ***p < 0.001. Combination index (CI) was calculated based on cell viability data using the CompuSyn software.
Results
Characterization and biodistribution of bone marrow-targeted BTNPs
We designed a core-shell structure for the BTNP to specifically deliver drug molecules to the bone marrow niches where MDS originates (Fig. 1a) . The shell of BTNP was composed of alendronate-conjugated PEG-DSPE for bone targeting, and the PLGA-cholesterol core incorporated DCA and ATO together. The core-shell structure and overall morphology of BTNP were confirmed by SEM, TEM, and AFM, respectively (Fig. 1b-d) . The solid core of BTNPs can be seen in the SEM image. The negative staining TEM image showed the lipid shell on the surface of BTNPs. AFM image showed the 3D overall morphology of BTNP. Changes in the lipid-to-polymer ratio resulted in alterations in particle size and surface charge (Fig. 1e) . However, alterations in drug composition or ratio did not significantly change particle size (Table   S1 ). DAC and ATO were co-encapsulated into BTNPs with high encapsulation efficiency from 79.2% to 87.5%. BTNPs-ATO had the highest total drug loading and encapsulation efficiency: 4.38% and 87.5%. This is likely due to the faster diffusion of DAC from the BTNP embryo emulsion compared to ATO, which causes more drug leakage during the encapsulation process. The faster diffusion from BTNPs could also be seen from the higher in vitro release rate of DAC compared to ATO. The in vitro release of DAC and ATO from BNTPs showed that the initial release of both drugs increased with increased content of DAC in BNTPs. Over 72 h, BTNPs (3:1) and BTNPs (2:1) achieved release of > 80% of the total drug loaded (Fig. S1) . The stable size of BTNPs in 50% FBS solution suggested the good stability of BTNPs and no aggregation in the presence of serum (Fig. S2) . Bone targeting ability of BTNPs was confirmed in the in vivo biodistribution study where fluorescently labeled BTNPs were used to treat mice with MDS (NUP98/ HOXD13 transgenic mice). Mice administered with BTNPs showed increased retention in all bone tissues (femur, spine, and skull) 24 h later when compared to those treated with untargeted NPs (Fig. 1f, h-j) , whereas the florescent dye was mainly retained in kidneys and spleen 24 h after administration (Fig. 1g) .
Synergistic inhibition of MDS cell growth by BTNP-packaged DAC and ATO
MDS and wild-type bone marrow cells were treated with BTNPpackaged DAC and ATO, and cell viability was examined. In general, we observed an ATO-concentration dependent cell killing, and inclusion of DAC in the formulations enhanced the cytotoxic effect (Fig. 2a) . On the contrary, DAC alone at low concentration (0.01 to 1 μg/mL) and blank NPs resulted in almost no growth inhibition effects on MDS cells (Fig.  S3) . All three formulations with DAC: ATO ratios within 1:1 to 3:1 showed synergistic MDS cell killing, as the combination index (CI) was well below 1 (Fig. 2b) . Differential cell killing between MDS and wildtype bone marrow cells was observed within 0.01 to 0.5 equivalent ATO concentration range for these three formulations. When treated with the BTNP (2:1) formulation containing DAC/ATO at a 2/1 ratio, viability of MDS cells stayed at 63%, 43%, and 33% at 0.01, 0.1, and 0.5 μg/mL equivalent ATO concentration, respectively; in comparison, viability of wild-type bone marrow cells stayed at 89%, 70%, and 63% when treated with the same dosages (Fig. 2c) . In addition, formulation into nanoparticles enhanced MDS cell killing, especially at the 0.01 to 0.5 equivalent ATO concentration range (Fig. 2d) . Ideally, BTNPs should have high cell growth inhibition on MDS cells and low cell cytotoxicity on WT cells. Among all the different formulations, only BTNPs (1:1) and BTNPs (2:1) showed the lowest cytotoxicity in WT cells and high synergistic effect in MDS cells. However, In vitro release studies showed that BTNPs (1:1) could not achieve complete release of both drugs. Therefore, BTNPs (2:1) was selected for further studies.
BTNP-packaged DAC and ATO kills MDS cells by triggering cell apoptosis
Arsenic trioxide-induced apoptosis has been shown to result in therapeutic efficacy in MDS patients [38] . We compared apoptosis of MDS cells treated with drugs in their free form, in untargeted nanoparticles or in BTNP. While all three treatments caused cell apoptosis at with an equivalent concentration of ATO of 0.1 μg/mL, apoptotic cells were more than twice as many in samples treated with drugs packaged in nanoparticles than those with the same dosage of free drugs (Fig. 3a) . Comparable cell killing by the targeted and untargeted nanoparticles was expected in the in vitro experiment, as bone niche targeting was not necessary for the particle to reach the cells. Flow cytometer analysis corroborated effective cell killing by the packaged drug combination (Fig. 3b) . Overall, these results further demonstrate the advantages of drug co-delivery over free drugs for MDS treatment.
Pharmacokinetics and biodistribution studies of BTNPs
Pharmacokinetic analyses of ATO (Fig. 4a) and DAC (Fig. 4b) showed that BTNP delivery resulted in two to three orders of magnitude higher plasma drug concentration than the free drugs 12 h after injection. In addition, BTNPs showed sustained release of DAC and ATO for up to 72 h. The area under curve (AUC (0-∞) ) of DAC in BTNP (2:1) was 4.5 times as high as free DAC, and that of ATO in BTNP (2:1) was 3.3 times over free ATO (Table 1) . Biodistribution ATO and DAC from the free drugs, untargeted particles and BTNPs in MDS mice revealed that, although most nanoparticles accumulated in the liver 24 h after intravenous injection, there were 6.7-fold 7.9-fold more DAC and ATO from BTNPs accumulated in the femur than untargeted NPs, respectively (Fig. 4 c, d ). No significant difference was observed on drug distribution in the other major organs including kidneys, spleen, lungs, and heart. These results indicate that BTNPs effectively targeted bone tissues and significantly enhanced drug accumulation in the bone marrow where the MDS cells locate.
Bone marrow enrichment of drug molecules provides therapeutic benefit in a murine model of MDS
The therapeutic goal for MDS is to achieve hematologic improvement and alteration of the disease's natural development. To evaluate efficacy of targeted nanoparticles in mice with MDS, CBC was measured weekly after treatment as indicator of hematologic improvement. Four weeks after BTNP treatment, WBC count increased in 62.5% of the mice, and was restored to normal levels in 50% of the mice (Fig. 5a ). In comparison, WBC count increased in only 31.3% and 37.5% of the mice treated with free drugs and untargeted particles, respectively, with only 25% of mice displayed restored WBC count to normal levels in these groups. In the meanwhile, 56.2% of BTNP treated mice had increased platelet counts, with 50% of them displaying platelet counts in the normal range. In the free drug and untargeted particles treated groups, only 31.3% and 37.5% of the mice showed increased platelet counts, and 31.1% of mice had platelet counts restored to normal range in these groups. (Fig. 5b) . No increased in RBC counts was seen in the control group, while three mice presented further decreased RBC levels (Fig. 5c) . Paired t-test analysis showed significant decrease of WBC, PLT and RBC in the PBS group after treatment, caused by MDS progression. On the contrary, in all drug treatment groups, CBCs were improved when compared with the PBS group. However, it should be noted that BTNPs treated mice showed significant increase in CBCs when compared to all the other treatments (free drugs and untargeted NPs). As a result, mice treated with BTNP showed significantly longer median survival than those treated with untargeted nanoparticles or free drugs (Fig. 5d) . Interestingly, treatment with untargeted drug nanoparticles did not provide a significant survival benefit over the free drug combination, highlighting the importance of bone marrow enrichment of the drug molecules through targeted drug delivery.
Analysis of blood smears provided further support for the therapeutic benefit from the treatment. Smears of peripheral blood from each group were analyzed to examine morphology of the hematopoietic cells (Smears of bone marrow cells did not show). Mice presented dysplastic cells in the PBS control group as indicated by black arrows (Fig. 5e) . In treatment groups with DAC and ATO, myelodysplastic status got relieved. For the mice with favorable response, dysplastic cells disappeared and the number of platelets appeared to be obviously increased in PB smears especially in BTNPs target treatment group (Fig. 5h) . It was kind of hard to find the platelets on PB smears of these mice due to thrombocytopenia (Fig. 5e-g ). These results suggested that myelodysplastic syndrome could be best controlled in BTNPs target treatment group. 3.6. BNTP-delivered drugs inhibit DNMT1 and trigger apoptosis in bone marrow
MDS cells
It has been previously reported that DAC is used to demethylate MDS through selective inhibition of DNA methyltransferase1 (DNMT1) [39] . We performed quantitative PCR analysis to analyze DNMT1 expression in bone marrow cells after treatment with BTNP-delivered drugs. DNMT1 mRNA levels in the free drug and untargeted NP treatment groups decreased by 43% comparing to the PBS control group; in comparison, DNMT1 mRNA dropped by 80% in the BTNP treatment group (Fig. 6a) . This result showed that BTNP could more efficiently inhibit DNMT1 than untargeted NPs and free drugs. Cell cytotoxicity of decitabine was mainly mediated through DNA damage [40] . γH2AX, a biomarker for DNA damage response, was measured by flow cytometric analysis to evaluate DNA damage after treatment with DAC (Fig. 6b) . Intensity of fluoresce presented γH2AX expressing level. MDS bone marrow cell treated with BTNPs had the lowest level of γH2AX. This suggests that DNA of MDS bone marrow cell was protected more efficiently upon treatment with BTNPs. These results suggest that BTNPs enhanced demethylation function of DAC to improve therapy efficacy on MDS and reduced DNA damage by DAC when compared to untargeted NPs and free drugs.
Flow cytometer was also performed to determine bone marrow cell apoptosis after treatment with BTNPs. Apoptosis rates in free drug and untargeted NPs treatment groups increased by 3.5-4.2 folds comparing to the PBS group, and BTNP treatment further induced apoptosis (Fig. 6c) . Thus, targeted delivery of ATO through BTNP could enhance apoptotic effects of ATO on bone marrow cells. As indicated by the yellow arrows in (Fig. 6d-g ), obvious cell apoptosis can be seen in the livers of groups treated with free ATO and untargeted nanoparticles, while comparable levels of apoptotic cell were found in the control group (PBS) and BTNPs treated groups. These data show that BTNPs could significantly reduce hepatotoxicity caused by non-specific action of ATO.
Discussion
Clinical use of many chemotherapy drugs is currently limited by the potential toxic effect on both tumor and healthy cells [41] . In fact, it is still a challenge to develop efficient and safe delivery systems capable of targeted delivery of chemotherapy drugs to the tumor site. A selective increase of drug concentration in the bone marrow is required to reduce systemic toxicity and increase efficacy in the treatment of MDS and other bone marrow related malignant tumors. Nanoparticles so far developed for targeting bone marrow include two major classes: liposomal-based and polymeric-based bone targeting [42] . Both these approaches present specific advantages for drug delivery. However, they both also exhibit limitations that significantly hinder clinical application. To combine the unique advantage of both polymeric nanoparticles and liposomes, and overcome their specific drawbacks, we developed a new class of bone-targeting nanoparticles, BTNPs, for the co-delivery of ATO and DAC. BTNPs developed in this work exhibit high drug loading efficiency, sustained-release profiles, good colloidal stability, specific bone-targeting ability and uniform size distribution. In our study, BTNPs composition for therapeutic efficacy studies was selected to be 20% lipid and 80% polymer to obtain a size in the 10 nm-100 nm range, optimal for endocytosis uptake in tumor cells [43] . In addition, BTNPs display good colloidal stability due to the presence of PEG on the surface, which prevents protein adsorption and aggregation of nanoparticles. This property presents significant additional advantage of BTNPs over polymeric particles since polymeric particles have been reported to easily aggregate in serum due to their hydrophobic surface [25] . We demonstrated that our BTNPs have an 87.5% ATO loading efficiency, whereas previous studies report only a 26.3% loading efficiency by liposomal formulation [44] . We also demonstrated a sustained release of ATO from BTNPs over 72 h, while a previous study reported > 60% ATO being released within only 3 h from a liposomal formulation [44] . Similar results were observed in another study on DAC release from liposomes, where > 90% DAC was released within the first 24 h [45] . On the contrary, BTNPs exhibit sustained-release of DAC three times longer when compared to liposomal formulations. Overall, BTNPs inherit high loading efficiency and sustained release profile from polymeric nanoparticles and exhibit good colloidal stability benefiting from PEG-lipid layer.
With our study, we demonstrated that BTNPs co-encapsulation also enhances synergistic effect of ATO and DAC on MDS cells. DAC is known to have potential demethylation effects on MDS cells, but no growth inhibition effect at low concentrations [46, 47] . On the contrary, ATO has been reported to reduce MDS cell viability by inducing apoptosis [48] . Our results not only confirm these findings, but also demonstrate complete synergistic effect of DAC and ATO in BTNPs formulations containing higher DAC/ATO ratios (1:1 to 3:1). It should be noted that a synergistic effect was also observed in the free mixture of DAC/ATO (2:1) when compared to DAC and ATO alone. However, the IC50 of the free mixture DAC/ATO (2:1) was still much higher than that of BTNPs (2:1). Thus, BTNP formulation (2:1) further increased the synergistic effects of DAC and ATO on MDS cells compared to the free mixture DAC/ATO (2:1). This benefit is likely owed to intrinsic advantages of nanoparticle-based delivery over the free form, namely enhanced cell uptake (Fig. 3 b-d) and sustained drug release. Unexpectedly, BTNPs (0.5:1) shows higher IC50 than BTNPs ATO, which suggests a possible antagonistic effect of BTNPs (0.5:1) at low fraction of affected cells, and synergistic effect at high fraction of affected cells. This type of contradicting behavior of two drugs at different ratio has been previously reported for others combinatorial drugs [49] .
Our plasma concentration studies of BTNPs-treated MDS mice showed sustained release of drugs from BTNPs in vivo, confirming our in vitro results. As expected, BTNPs and untargeted NPs showed no significant difference in targeting MDS bone marrow cell apoptosis in vitro, while BTNPs significantly enhanced accumulation of nanoparticles in the bone marrow niche of MDS mice. Tissue distribution analysis showed that BTNPs enabled increase accumulation of DAC and ATO in the bone marrow up to 6.7-fold and 7.9-fold, respectively. In previous literature, the in vivo biodistribution of alendronate conjugated polymer (PTX-PEG-ALN, DOX-hyd-PEG-ALN) micelles for bone targeted delivery of paclitaxel and doxorubicin increased only around 3 and 4 fold accumulation of drugs in bone, respectively [22, 23] . The more efficient bone targeting of BTNPs with respect to alendronate conjugated polymeric micelles can be attributed to enhanced bone marrow absorption and reduced burst release profile of BTNPs. The lipid layer surrounding BTNPs facilitates uptake by MDS cells due to its cell compatibility. More importantly, the lipid layer enhances drug retention in BTNPs during the initial release phase [25] .This will maximally increase drug accumulation in targeted tissues during BTNP-delivery. The in vivo biodistribution of alendronate-conjugated liposomes (LIP-ALN) has not been investigated, but a comparison can be performed based on loading efficiency. BTNPs' loading efficiency is significantly higher when compared to alendronate-conjugated liposomes (89% for BTNPs vs 34%-50% for LIP-ALN) [24] . This advantage of BTNPs likely results from their polymeric core.
In our study we evaluated therapeutic efficacy by monitoring WBC and PLT, two important indexes for diagnosis of MDS in clinic. BTNPs significantly increased percentages of recovered WBC and PLT in MDS mice compared to free drugs and untargeted NPs. Notably, the sustained release advantage of untargeted NPs was not sufficient to result in significant changes in CBC and survival time when compared to free drugs. This stresses the importance of bone marrow targeting to reach sufficient levels of drug accumulation in bone marrow. These results could additionally explain why no single patient has shown complete remission in a recent phase I clinical study on MDS treatment with combination of free DAC and ATO (three stable disease; two progressions) [5] . Therefore, our promising results in mice suggest that targeted delivery to bone marrow through BTNPs could greatly improve outcome for MDS patients in clinic. BTNP co-delivery of DAC and ATO not only improved therapeutic efficacy, but also reduced systemic toxicity by increasing drug accumulation in the bone marrow of MDS mice. Decitabine treatment of MDS has been reported to have cytotoxic effects on bone marrow cells, requiring pulse-cycled administration to minimize cytotoxicity and increase DNMT1 depletion [44] . Compared to the combination of free drugs and untargeted NPs, BTNPs result in greater DNMT1 depletion, without increasing DNA damage to healthy bone marrow cells. This is likely a benefit due to sustained release and bone targeting properties of BTNPs, which ensures a high enough DAC concentration for effective DNMT1 depletion, but no cell toxicity to bone marrow cells. Hepatotoxicity through liver cell apoptosis is instead the main systemic toxicity caused by arsenic trioxide [50] . However, a significant reduction of apoptotic liver cells was seen in BTNPs treated MDS mice as a result of the bone targeting ability of BTNPs. Overall, our data support further clinical translation of BTNPs to improve current outcome of MDS with low systemic toxicity in clinic.
Conclusions
In this study, DAC and ATO were co-delivered in a bone-targeting polymeric/lipid nanoparticle formulation (BTNP) for MDS treatment, and resulted in a dual-acting synergistic mechanism. Our in vitro studies suggested that BTNPs (DAC:ATO = 2:1) exhibited synergistic enhancement of MDS cell growth inhibition, while reducing cell toxicity in WT cells. Thanks to their targeting ability, BTNPs showed a great advantage also in the in vivo treatment of an MDS mouse model with respect to free drugs and delivery via untargeted nanoparticles. BTNPs also significantly reduced hepatotoxicity, the main adverse effect of ATO in clinic. In conclusion, using BTNPs to co-deliver DAC and ATO, not only generated synergistic effect in the treatment of MDS cells in a mouse model, but also reduced systemic toxicity. These studies suggest that BTNPs could provide an efficient combinatorial strategy for bonetargeted treatment of MDS in the clinic.
